This conversation is particularly important for individuals with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2 (MEN 2), as these represent absolute contraindications to the use of products with the thyroid C-cell tumor boxed warning, including semaglutide, liraglutide, dulaglutide, exenatide extended-release, and tirzepatide
Men taking medications that may interact with peptide therapy should be reviewed by a physician, especially if they use diabetes medications, blood pressure drugs, hormone therapy, steroids, or medications affecting appetite, sleep, or metabolism
Pharmacists should be cautious when patients use chromium alongside insulin or other glucose-lowering therapies because of the risk of additive glucose-lowering effects
What the federal agreement changes While the full details will roll out in phases, the agreement centers on two essential goals: Lowering the list price of GLP-1 drugs Manufacturers have agreed to reduce baseline pricing, which may especially help Westporters who: Pay cash Use high-deductible insurance plans Have partial coverage Rely on savings programs Reduced manufacturer prices often lead to lower pharmacy prices over time